Abstract
Anemia is a common complication of acute and chronic renal failure and prior to the onset of ESRD, it is a usual clinical feature of renal insufficiency. Correction of the anemia associated with renal disease by erythropoietin (EPO) treatment, has proven to be a major contribution to the general medical care of patients with renal failure. Aside from clinically significant improvement in hematocrit, EPO treatment has resulted in significant improvement in physical working capacity, appetite, physical well-being [1], cognitive performance [2], and sexual function [3].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Eshbach JW, Egrie JC, Downing MR, Brown JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med. 1987;316:73–8.
Nissenson AR, Marsh JT, Brown WS, Schweitzer S, Wolcott DL. Brain function improves in chronic hemodialysis patients after recombinant erythropoietin. Kidney Int. 1989;35:25.
Bommer J, Alexiou C, Muller-Buhl U, Eifery J, Ritz E. Recombinant human erythropoietin therapy in heamodiallysis patients — dose determination and clinical experience. Nephrol Dial Transplantation. 1987;2:238–42.
Mark J, Bondurant MC. Erythropoietin retards DAN breakdown and prevents programmed death in erythroid progenitor cells. Science. 1990;248:376–81.
Spivak JL, Pham T, Isaacs M, Hankins D. Erythropoietin is both a mitogen and a survival factor. Blood. 1991;177:1228–33.
Zachee P, Ferrant A, Daelemans R, Coolen L, Goossens W, Lins RL, Coutteye X, De Broe ME, Boogaerts MA. Oxidative injury to erythrocytes, cell rigidity and splenic hemolysis in hemodialyzed patients before and during erythropoietin treatment. Nephron. 1993;65:288–93.
Joske RA, McAlister JM, Prankert TAJ. Isotope investigations of red cell production and destruction in chronic renal disease. Clin Sci. 1956;15:511–22.
William SK, Howarth NL, Devenny JS, Bitensky MW. Structural and functional consequences of increased tubulin glycosylation in diabetes mellitus. Proc Natl Acad Sci USA. 1982;79:6546–50.
Weiss MP, Rodby AR, Justice AC, Hricik DE and The Colavorative Study Group. Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy. Kidney Int. 1998;54:193–202.
Sebekova K, Blakzick P, Syrova D, Krivosikova Z, Soustova V, Heidland A, Schinzel R. Circulating advanced glycation end product level in rats rapidly increase with acute renal failure. Kidney Int. 2001;78:S58-S62.
Capeillere-Blandin C, Delaveau T, Descamps-Latxha B. Structural modification of human B2 microglobulin treated with oxygen-derived radicals. Biochem J. 1991; 277:175–82.
Vlassara H. Advanced location end-products atherosclerosis. Ann Int Med. 1996; 28:419–26.
Niwa T, Tsukushi S. 3-Deoxyglucosone and AGEs in uremic complications: inactivation of glutathione peroxidase by 3-deoxyglucosone. Kidney Int. 2001; 78:S37-S41.
Macdugall IC, Davies ME, Hutton RD, Coles GA, Williams JD. Rheological studies during treatment of renal anemias with recombinant human erythropoietin. Br J Hematol. 1991;77:550–8.
Zender C, Blumberg A. Human recombinant erythropoietin treatment in transfusion dependent anemic patient on maintenance hemodialysis. Clin Nephrol. 1989;31:55–9.
Cotes PM, Pippaard MJ, Reid CDL, Winearls CG, Oliver DO, Royston JP. Characterization of anemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin. An investigation of the pharmacokinetics of intravenous erythropoietin and its effect on erythrokinetics. QJ Med. 1989;7:113–37.
Polenakovic M, Sikole A. Is erythropoietin a survival factor for red blood cells? J Am Soc Nephrol. 1996;7:1178–82.
Schwartz AB, Kahn SB, Kelch B, Kim KE, Pequignot E. RBC improved survival due to recombinant human erythropoietin explains effectiveness of less frequent, low dose subcutaneous therapy. Clin Nephrol. 1992;38:283–9.
Brown CD, Zhao ZH, Thomas LL, deGroof R, Friedman EA. Effects of erythropoietin and aminoguanidine of red blood cell deformability in diabetic azotemic and uremic patients. Am J Kid Dis. (in press).
Brown CD, Zhao ZH, DeAlvaro F, Chan S, Friedman EA. Correction of erythrocyte deformability defect in ALX-induced diabetic rabbits after treatment with aminoguanidine. Diabetes. 1993;16:590–3.
Fischer C, Scigalla P, Park W, Becker H, Schiller R, Paust H, Broesicke H, Kessel M. influence of rhEPO therapy on the protein metabolism of hemodialysis patients with terminal renal insufficiency. Contrib Nephrol. 1989;76;250–6.
Nicl T, Lapolla A, Arico CN, Gammaro L, Bernich P, Fedele D. Hemodialysis techniques and advanced glycation end products. Contrib Nephrol. 2001;131: 33–9.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Brown, C.D., Zhao, Z.H., Thomas, L.L., deGroof, R., Friedman, E.A. (2002). Does treatment with EPO improve RBC survival?. In: Ifudu, O. (eds) Renal Anemia. Springer, Dordrecht. https://doi.org/10.1007/978-94-015-9998-6_2
Download citation
DOI: https://doi.org/10.1007/978-94-015-9998-6_2
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-6045-7
Online ISBN: 978-94-015-9998-6
eBook Packages: Springer Book Archive